WO2025093926 - A METHOD OF MINIMIZING OR ELIMINATING NEPHROTOXICITY IN PATIENTS UNDERGOING CISPLATIN-BASED CHEMOTHERAPY VIA SEQUENTIAL ADMINISTRATION OF A PROTECTIVE AGENT FOLLOWED BY A TOXIC AGENT
National phase entry is expected:
Publication Number
WO/2025/093926
Publication Date
08.05.2025
International Application No.
PCT/IB2024/000620
International Filing Date
04.11.2024
Title **
[English]
A METHOD OF MINIMIZING OR ELIMINATING NEPHROTOXICITY IN PATIENTS UNDERGOING CISPLATIN-BASED CHEMOTHERAPY VIA SEQUENTIAL ADMINISTRATION OF A PROTECTIVE AGENT FOLLOWED BY A TOXIC AGENT
[French]
PROCÉDÉ DE MINIMISATION OU D'ÉLIMINATION DE LA NÉPHROTOXICITÉ CHEZ DES PATIENTS SUBISSANT UNE CHIMIOTHÉRAPIE À BASE DE CISPLATINE PAR ADMINISTRATION SÉQUENTIELLE D'UN AGENT PROTECTEUR SUIVI D'UN AGENT TOXIQUE
Applicants **
NIIGATA UNIVERSITY
Inventors
SAITO Akihiko
KABASAWA Hideyuki
HOSOJIMA Michihiro
Priority Data
63/595,636
02.11.2023
US
2024-089392
31.05.2024
JP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2687 | |
| EPO | Filing, Examination, Granting | 12529 | |
| Japan | Filing, Examination, Granting | 2326 | |
| South Korea | Filing, Examination, Granting | 2393 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,675
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
In one aspect, the invention relates to methods of treating nephrotoxicity in a subject comprising administering a therapeutically effective amount of a megalin antagonist such as, for example, cilastatin, wherein the subject is undergoing platinum-based and/or antimicrobial therapy, previously underwent platinum-based and/or antimicrobial therapy, or is going to begin platinum-based and/or antimicrobial therapy. Also disclosed are methods of reducing/mitigating or preventing nephrotoxicity in a subject comprising administering a therapeutically effective amount of a megalin antagonist, wherein the subject is undergoing platinum-based and/or antimicrobial therapy, previously underwent platinum-based and/or antimicrobial therapy, or is going to begin and/or antimicrobial platinum-based therapy. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.[French]
Selon un aspect, l'invention concerne des méthodes de traitement de la néphrotoxicité chez un sujet, comprenant l'administration d'une quantité thérapeutiquement efficace d'un antagoniste de mégaline tel que, par exemple, la cilastatine, le sujet subissant une thérapie à base de platine et/ou une thérapie antimicrobienne, ayant préalablement subis une thérapie à base de platine et/ou une thérapie antimicrobienne, ou allant débuter une thérapie à base de platine et/ou une thérapie antimicrobienne. L'invention concerne également des méthodes de réduction/atténuation ou de prévention de la néphrotoxicité chez un sujet, comprenant l'administration d'une quantité thérapeutiquement efficace d'un antagoniste de mégaline, le sujet subissant une thérapie à base de platine et/ou une thérapie antimicrobienne, ayant préalablement subis une thérapie à base de platine et/ou une thérapie antimicrobienne, ou allant débuter une thérapie à base de platine et/ou une thérapie antimicrobienne. Le présent abrégé est proposé à titre d'outil d'exploration à des fins de recherche dans cette technique particulière et n'est pas destiné à limiter la présente invention.